News

Polymyalgia Rheumatica: Steroids and Beyond : Lower doses of prednisone and a greater use of biologics are on the PMR treatment horizon.


 

In contrast, antitumor necrosis factor therapy using etanercept or infliximab has compiled an unimpressive record overall for PMR in case reports and pilot studies.

“At present, I think there is no role for antitumor necrosis factor therapy in PMR,” he said.

Disclosures: Dr. Cimmino disclosed having received research grants from numerous pharmaceutical companies, including Roche, Schering Plough, Abbott, and Pfizer.

Pages

Recommended Reading

Many With Foot, Ankle Pain Drop Out of Care : Despite wide prevalence, it remains unclear that the condition is due to musculoskeletal ills.
MDedge Rheumatology
Foot Care Falls Short in RA, Despite High Pathology Rate
MDedge Rheumatology
Elderly Receive Suboptimal RA Treatment
MDedge Rheumatology
RA Patients on the Frontier Of Joint Replacement
MDedge Rheumatology
Framingham Approach Needed in Back Pain
MDedge Rheumatology
TNF Inhibitor Significantly Slowed RA Progression
MDedge Rheumatology
RA Subset Responds to Higher Rituximab Dose
MDedge Rheumatology
ACR/EULAR Criteria Found Valid at 2 Years
MDedge Rheumatology
Biologics Highlighted in Joint AS Guidelines : ASAS and EULAR collaborated to revise this document on ankylosing spondylitis management.
MDedge Rheumatology
New Score Aims to Improve AS Evaluation and Care
MDedge Rheumatology